z-logo
Premium
Nocistatin inhibits 5‐hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways
Author(s) -
Fantin M,
Fischetti C,
Trapella C,
Morari M
Publication year - 2007
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0707377
Subject(s) - nociceptin receptor , nop , chemistry , antagonist , receptor , g protein , medicine , (+) naloxone , neuropeptide y receptor , pertussis toxin , endocrinology , gtpgammas , neuropeptide , pharmacology , opioid , biochemistry , biology , opioid peptide
Background and purpose: Nocistatin (NST) is a neuropeptide generated from cleavage of the nociceptin/orphanin FQ (N/OFQ) precursor. Evidence has been presented that NST acts as a functional antagonist of N/OFQ, although NST receptor and transduction pathways have not yet been identified. We previously showed that N/OFQ inhibited [ 3 H]5‐hydroxytryptamine ([ 3 H]5‐HT) release from mouse cortical synaptosomes via activation of NOP receptors. We now investigate whether NST regulates [ 3 H]5‐HT release in the same preparation. Experimental approach: Mouse and rat cerebrocortical synaptosomes in superfusion, preloaded with [ 3 H]5‐HT and stimulated with 1 min pulses of 10 mM KCl, were used. Key results: Bovine NST (b‐NST) inhibited the K + ‐induced [ 3 H]5‐HT release, displaying similar efficacy but lower potency than N/OFQ. b‐NST action underwent concentration‐dependent and time‐dependent desensitization, and was not prevented either by the NOP receptor antagonist [Nphe 1 Arg 14 ,Lys 15 ]N/OFQ(1‐13)‐NH 2 (UFP‐101) or by the non‐selective opioid receptor antagonist, naloxone. Contrary to N/OFQ, b‐NST reduced [ 3 H]5‐HT release from synaptosomes obtained from NOP receptor knockout mice. However, both N/OFQ and NST were ineffective in synaptosomes pre‐treated with the G i/o protein inhibitor, Pertussis toxin. NST‐N/OFQ interactions were also investigated. Co‐application of maximal concentrations of both peptides did not result in additive effects, whereas pre‐application of maximal b‐NST concentrations partially attenuated N/OFQ inhibition. Conclusions and implications: We conclude that b‐NST inhibits [ 3 H]5‐HT release via activation of G i/o protein linked pathways, not involving classical opioid receptors and the NOP receptor. The present data strengthen the view that b‐NST is, per se , a biologically active peptide endowed with agonist activity. British Journal of Pharmacology (2007) 152 , 549–555; doi: 10.1038/sj.bjp.0707377 ; published online 9 July 2007

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom